Want to see NNVC full AI Analyst Report?
Top Page
NanoViricides
(NNVC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▲(17.19% Upside)
Action:Reiterated
Date:09/30/26
The score is primarily held down by weak financial performance (pre-revenue profile, persistent losses, and ongoing negative operating/free cash flow), despite low debt. Technical indicators are broadly neutral with only modest positive momentum. The recent financing helps liquidity and supports operations, but valuation remains challenged due to losses and no dividend yield provided.
Positive Factors
Minimal financial leverage
Minimal debt reduces refinancing and interest-rate exposure while preserving financial flexibility relative to a highly leveraged biotechnology company. This balance-sheet advantage may help NanoViricides direct available capital toward research and clinical development rather than servicing substantial borrowing obligations.
Negative Factors
No revenue and persistent losses
A zero-revenue profile and recurring operating losses show that the company has not yet established a commercial revenue base to fund its activities. Continued losses leave future progress dependent on external capital or successful development and commercialization of investigational antiviral candidates.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal financial leverage
Minimal debt reduces refinancing and interest-rate exposure while preserving financial flexibility relative to a highly leveraged biotechnology company. This balance-sheet advantage may help NanoViricides direct available capital toward research and clinical development rather than servicing substantial borrowing obligations.
Read all positive factors
NanoViricides (NNVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.67M
Dividend YieldN/A
Average Volume (3M)557.06K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue GrowthN/A
EPS Growth35.47%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding25,525,000
10 Day Avg. Volume426,034
30 Day Avg. Volume557,056
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-89.84
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$6.00Price Target Upside368.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
NanoViricides Business Overview & Revenue Model
Company Description
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coro...
How the Company Makes Money
null...
NanoViricides Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -525.29K | 0.00 | 0.00 | -747.53K | 0.00 |
| EBITDA | -7.78M | -8.72M | -7.49M | -7.84M | -7.38M |
| Net Income | -8.22M | -9.47M | -8.29M | -8.59M | -8.11M |
Balance Sheet | |||||
| Total Assets | 9.87T | 8.82M | 12.82M | 16.90M | 23.49M |
| Cash, Cash Equivalents and Short-Term Investments | 2.79T | 1.56M | 4.80M | 8.15M | 14.07M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 94.79K |
| Total Liabilities | 1.19T | 1.31M | 1.36M | 2.03M | 412.84K |
| Stockholders Equity | 8.68T | 7.52M | 11.46M | 14.87M | 23.08M |
Cash Flow | |||||
| Free Cash Flow | -7.78T | -8.54M | -6.47M | -5.82M | -6.22M |
| Operating Cash Flow | -7.70T | -8.48M | -6.32M | -5.67M | -5.89M |
| Investing Cash Flow | -84.32B | -56.96K | -156.56K | -151.71K | -324.35K |
| Financing Cash Flow | 9.02T | 5.30M | 3.12M | -94.79K | -234.72K |
NanoViricides Technical Analysis
Negative
1.28
Price Trends
1.32
Negative
1.41
Negative
1.28
Positive
Market Momentum
<0.01
Positive
46.53
Neutral
21.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Negative. The current price of 1.28 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 1.32, and above the 200-day MA of 1.28, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 21.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NNVC.
NanoViricides Risk Analysis
NanoViricides disclosed 51 risk factors in its most recent earnings report. NanoViricides reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Summary of Risk Factors Q2, 2025
NanoViricides Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $257.49M | 0.79 | -6.74% | ― | -100.00% | 95.16% | |
46 Neutral | $32.67M | -3.11 | >-0.01% | ― | ― | 35.47% | |
46 Neutral | $14.95M | >-0.01 | -147.45% | ― | ― | ― | |
44 Neutral | $5.04M | ― | 279.88% | ― | ― | ― | |
44 Neutral | $8.44M | -0.02 | -816.56% | ― | ― | 85.06% |
* Healthcare Sector Average
NNVC
NanoViricides
1.32
-0.03
-2.22%
ENLV
Enlivex
0.22
-16.43
-98.67%
AKTX
Akari Therapeutics
7.90
-31.30
-79.85%
MBRX
Moleculin Biotech
0.44
-11.94
-96.48%
SABS
SAB Biotherapeutics
2.68
0.38
16.52%
NanoViricides Corporate Events
Business Operations and StrategyPrivate Placements and Financing
NanoViricides Announces $3.8 Million Registered Direct Offering
Positive
Jul 30, 2026
On July 24, 2026, NanoViricides entered a securities purchase agreement with a single institutional investor for a registered direct offering of 2,516,339 common shares or pre‑funded warrants, plus accompanying warrants for an equal number o...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
NanoViricides Establishes ATM Equity Sales Agreement
Neutral
Jul 17, 2026
On July 17, 2026, NanoViricides entered into an at‑the‑market issuance sales agreement with D. Boral Capital LLC, allowing the company to offer and sell shares of its common stock from time to time through the sales agent on the NYSE A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.